Key takeaways
- Stopping GLP-1 drugs for two years is linked to a 22% higher risk of heart attack, stroke, and death.
- Longer gaps in GLP-1 treatment correlate directly with higher cardiovascular risks.
- Almost half of first-time semaglutide users stop taking the medication within the first year, often due to high brand-name costs.
- Compounded GLP-1 alternatives through telehealth can provide a lower-cost path to maintaining continuous treatment.
What happened
A new study has revealed that halting GLP-1 receptor agonist treatment is linked to a 22% higher risk of heart attack, stroke, and death over a two-year period compared to continuing therapy. The research, conducted by investigators at the Washington University School of Medicine and highlighted in a report by Axios, shows that the longer a patient remains off these medications, the more their cardiovascular risk escalates.
Why it matters
For millions of Americans navigating the high cost of brand-name weight-loss drugs, this data highlights the significant clinical danger of treating GLP-1 therapy as a short-term fix. Many cash-paying patients face insurance denials or cannot afford to pay over $1,000 per month indefinitely, leading them to pause or quit their regimens.
These new findings suggest that stopping GLP-1 therapy does not simply reverse weight loss—it exposes patients to acute cardiovascular dangers. Because many people who are prescribed semaglutide (the active ingredient in Ozempic and Wegovy) or tirzepatide (Mounjaro and Zepbound) already live with obesity or type 2 diabetes, they are already predisposed to elevated cardiovascular and metabolic risks. Halting the medication appears to strip away the critical cardiovascular protection these therapies provide, leaving vulnerable patients exposed.
What the data says
The clinical evidence pointing to the risks of stopping GLP-1s is growing:
- Cardiovascular Events: The Washington University School of Medicine study found a 22% increased risk of experiencing a heart attack, stroke, or death within two years of stopping GLP-1 therapy compared to those who stayed on the medication.
- The Gap Effect: Researchers noted a direct correlation between the length of the treatment interruption and the level of risk: longer gaps in therapy translate to higher cardiovascular risks.
- Metabolic Rebound: A separate review published in the journal Diabetes, Obesity and Metabolism found that stopping GLP-1s leads to rapid increases in blood sugar levels, along with heightened risks of coronary artery disease and heart failure compared to continued therapy.
- Weight Regain: Previous research shows that patients who stop taking GLP-1 medications typically regain approximately two-thirds of the weight they lost while on the treatment.
- High Discontinuation Rates: This clinical risk is widespread. A recent study of more than 157,000 first-time semaglutide users found that 49% stopped taking the medication within their first year of treatment.
How it compares
For cash-paying patients in the United States, keeping up with brand-name GLP-1 medications can be financially unsustainable. Brand-name Wegovy and Zepbound carry retail prices ranging from $1,000 to $1,350 per month. If a patient loses insurance coverage or cannot sustain this out-of-pocket expense, they face the 22% spike in cardiovascular risks detailed in the study.
To avoid dangerous treatment gaps, many patients are turning to online weight-loss clinics. On our providers page, patients can compare licensed telehealth companies that offer more affordable options. For example, some platforms have drastically lowered the barrier to entry, such as when Oak launched $119 compounded GLP-1 plans to help squeeze cash-pay telehealth weight-loss pricing.
Using compounded semaglutide or compounded tirzepatide from regulated compounding pharmacies typically costs between $150 and $400 per month, making continuous, long-term therapy financially realistic for buyers who would otherwise be forced to stop treatment.
How this fits the bigger picture
This study adds critical context to the growing body of research establishing GLP-1s as cardiovascular therapies, not just cosmetic weight-loss drugs. We previously reported on how Novo’s Wegovy benefits frail heart patients based on data from the landmark SELECT trial, which proved the drug reduces major adverse cardiovascular events. The new data from Washington University acts as the flip side of that coin: if starting the drug reduces heart risks, stopping it reverses those protections and increases risks.
For patients trying to avoid these cardiovascular rebounds, the digital health market has shifted. Many US buyers are utilizing the CompareRx questionnaire to find clinical programs that offer cheaper, consistent pricing to prevent therapy gaps. While next-generation drug developments are underway, maintaining access to current medications is the most pressing issue for active patients.
What happens next
As researchers and clinicians grapple with high discontinuation rates, the pharmaceutical industry is looking for post-GLP-1 maintenance strategies. Axios reported that the biotechnology company Enveda is currently developing a daily pill specifically designed to help patients maintain their progress and weight loss after they stop GLP-1 therapy.
In the meantime, healthcare providers are urging patients not to abruptly stop their GLP-1 regimens without a clinical transition plan. Patients facing high costs are encouraged to explore alternative, lower-cost telehealth channels to maintain therapy and protect their cardiovascular health.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting, stopping, or altering any medication regimen.